Corient Capital Partners’s Ocugen OCGN Stock Holding History

Corient Capital Partners’s Portfolio OCGN Stock Details OCGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-12,080	Closed	-$87K	–	733
2021 Q3	$87K	Buy	+12,080	New	+$88.7K	0.01%	682

Other funds holding OCGN

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Corient Capital Partners's OCGN Position: Q4 2021 in Review

Corient Capital Partners sold out of Ocugen (OCGN) in Q4 2021, closing a stake of 12,080 shares — an estimated $87K sold.

Corient Capital Partners first reported a position in OCGN in Q3 2021 and held it in 1 quarter. The position peaked at $87K in Q3 2021. 122 funds tracked by Wall St. Rank hold OCGN as of Q4 2021.

Corient Capital Partners reported no remaining Ocugen position as of Q4 2021 after selling out during the quarter.
Corient Capital Partners sold 12,080 Ocugen shares in Q4 2021, an estimated $87K.
Corient Capital Partners first reported a position in Ocugen in Q3 2021 and held it in 1 quarter.
Corient Capital Partners's Ocugen position peaked at $87K in Q3 2021.
122 funds tracked by Wall St. Rank held Ocugen as of Q4 2021.

Based on Corient Capital Partners's 13F filing for Q4 2021, filed 11 Feb 2022.